Pharmacogenetics in neuroendocrine tumors of the pancreas

Syed M.ujtaba Rizvi, Joyce Wong, Muhammad W.asif Saif, Yuxia Jia

Research output: Contribution to journalReview article

Abstract

Neuroendocrine tumors (NETs) arise from cells distributed throughout the endocrine system. Although, NETs are heterogeneous in their behavior, they tend to be more aggressive when arising in the pancreas. Pancreatic NET (panNET) represents three percent of all primary pancreatic neoplasms. Symptomatic and progressive panNETs are generally treated with cytotoxic chemotherapy, whereas molecular targeted therapy is used for nonfunctional tumors without aggressive features. Pharmacogenetics has increasingly been used recently to better identify potential targets for therapy and help select patient-specific therapy. In this review, we discuss two abstracts (Abstracts #4113 and #e15169) presented at the ASCO Annual Meeting in Chicago this year, outlining the potential role of tumor gene and gene product profiling in disease management. We describe what is known about the pathogenesis of these tumors, role of decreased gene product expression (MGMT, RRM1, MET) and its application in cytotoxic therapy selection, as well as genetic mutations that can be used for molecular targeted therapy. With an overall shift towards personalized medicine, it has become ever more important to identify the molecular signature of a tumor as it appears to dictate the clinical behavior and response to therapy.

Original languageEnglish (US)
Pages (from-to)299-302
Number of pages4
JournalJOP : Journal of the pancreas
Volume15
Issue number4
DOIs
StatePublished - Jul 1 2014

Fingerprint

Neuroendocrine Tumors
Pharmacogenetics
Pancreas
Molecular Targeted Therapy
Neoplasms
Precision Medicine
Endocrine System
Therapeutics
Disease Management
Pancreatic Neoplasms
Genes
Gene Expression
Drug Therapy
Mutation

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Rizvi, Syed M.ujtaba ; Wong, Joyce ; Saif, Muhammad W.asif ; Jia, Yuxia. / Pharmacogenetics in neuroendocrine tumors of the pancreas. In: JOP : Journal of the pancreas. 2014 ; Vol. 15, No. 4. pp. 299-302.
@article{b1818d9d0f92451ea5b3767308eacd3b,
title = "Pharmacogenetics in neuroendocrine tumors of the pancreas",
abstract = "Neuroendocrine tumors (NETs) arise from cells distributed throughout the endocrine system. Although, NETs are heterogeneous in their behavior, they tend to be more aggressive when arising in the pancreas. Pancreatic NET (panNET) represents three percent of all primary pancreatic neoplasms. Symptomatic and progressive panNETs are generally treated with cytotoxic chemotherapy, whereas molecular targeted therapy is used for nonfunctional tumors without aggressive features. Pharmacogenetics has increasingly been used recently to better identify potential targets for therapy and help select patient-specific therapy. In this review, we discuss two abstracts (Abstracts #4113 and #e15169) presented at the ASCO Annual Meeting in Chicago this year, outlining the potential role of tumor gene and gene product profiling in disease management. We describe what is known about the pathogenesis of these tumors, role of decreased gene product expression (MGMT, RRM1, MET) and its application in cytotoxic therapy selection, as well as genetic mutations that can be used for molecular targeted therapy. With an overall shift towards personalized medicine, it has become ever more important to identify the molecular signature of a tumor as it appears to dictate the clinical behavior and response to therapy.",
author = "Rizvi, {Syed M.ujtaba} and Joyce Wong and Saif, {Muhammad W.asif} and Yuxia Jia",
year = "2014",
month = "7",
day = "1",
doi = "10.6092/1590-8577/2659",
language = "English (US)",
volume = "15",
pages = "299--302",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "4",

}

Pharmacogenetics in neuroendocrine tumors of the pancreas. / Rizvi, Syed M.ujtaba; Wong, Joyce; Saif, Muhammad W.asif; Jia, Yuxia.

In: JOP : Journal of the pancreas, Vol. 15, No. 4, 01.07.2014, p. 299-302.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Pharmacogenetics in neuroendocrine tumors of the pancreas

AU - Rizvi, Syed M.ujtaba

AU - Wong, Joyce

AU - Saif, Muhammad W.asif

AU - Jia, Yuxia

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Neuroendocrine tumors (NETs) arise from cells distributed throughout the endocrine system. Although, NETs are heterogeneous in their behavior, they tend to be more aggressive when arising in the pancreas. Pancreatic NET (panNET) represents three percent of all primary pancreatic neoplasms. Symptomatic and progressive panNETs are generally treated with cytotoxic chemotherapy, whereas molecular targeted therapy is used for nonfunctional tumors without aggressive features. Pharmacogenetics has increasingly been used recently to better identify potential targets for therapy and help select patient-specific therapy. In this review, we discuss two abstracts (Abstracts #4113 and #e15169) presented at the ASCO Annual Meeting in Chicago this year, outlining the potential role of tumor gene and gene product profiling in disease management. We describe what is known about the pathogenesis of these tumors, role of decreased gene product expression (MGMT, RRM1, MET) and its application in cytotoxic therapy selection, as well as genetic mutations that can be used for molecular targeted therapy. With an overall shift towards personalized medicine, it has become ever more important to identify the molecular signature of a tumor as it appears to dictate the clinical behavior and response to therapy.

AB - Neuroendocrine tumors (NETs) arise from cells distributed throughout the endocrine system. Although, NETs are heterogeneous in their behavior, they tend to be more aggressive when arising in the pancreas. Pancreatic NET (panNET) represents three percent of all primary pancreatic neoplasms. Symptomatic and progressive panNETs are generally treated with cytotoxic chemotherapy, whereas molecular targeted therapy is used for nonfunctional tumors without aggressive features. Pharmacogenetics has increasingly been used recently to better identify potential targets for therapy and help select patient-specific therapy. In this review, we discuss two abstracts (Abstracts #4113 and #e15169) presented at the ASCO Annual Meeting in Chicago this year, outlining the potential role of tumor gene and gene product profiling in disease management. We describe what is known about the pathogenesis of these tumors, role of decreased gene product expression (MGMT, RRM1, MET) and its application in cytotoxic therapy selection, as well as genetic mutations that can be used for molecular targeted therapy. With an overall shift towards personalized medicine, it has become ever more important to identify the molecular signature of a tumor as it appears to dictate the clinical behavior and response to therapy.

UR - http://www.scopus.com/inward/record.url?scp=84929288017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929288017&partnerID=8YFLogxK

U2 - 10.6092/1590-8577/2659

DO - 10.6092/1590-8577/2659

M3 - Review article

VL - 15

SP - 299

EP - 302

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 4

ER -